Data as of Q4 2025 (Dec 31, 2025)

Aardvark Therapeutics, Inc.

(AARD)

Financial Statements · SEC EDGAR XBRL

Net Income
-$57.6M
-179.7%
EPS
$-2.93
+43.1%
Op. Income
-$62.7M
-175.3%
FCF
-$54.3M
-198.2%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
$48.9M
$17.4M
$62.7M
$22.8M
-$62.7M
-$22.8M
$5.1M
$2.2M
$0
$0
-$57.6M
-$20.6M
$-2.93
$-5.15
$-2.93
$-5.15
19.6M
4.0M